Compare

20/20 Biolabs, Inc. vs UL Solutions Inc.

Latest annual figures from SEC filings. Each company is shown for its own most recent fiscal year, so period ends can differ. Select a figure to see its full history.

Latest fiscal year	20/20 Biolabs, Inc. AIDX	UL Solutions Inc. ULS
Year ended	2025-12-31	2025-12-31
Revenue	$2.05M	$3.05B
Revenue growth (YoY)	+16.7%	+6.4%
Gross margin	29.6%	49.5% (computed)
Operating margin	-162.9%	17.1%
Net margin	-182.8%	10.6%
Net income	-$3.74M	$325.00M
EPS (Diluted)	-$0.76	$1.60
Operating cash flow	-$1.92M	$600.00M
Free cash flow	n/a	$403.00M
Cash & equivalents	$1.03M	$295.00M
Total assets	$4.14M	$2.92B
Total liabilities	$4.16M	$1.63B
Shareholders' equity	-$19.2K	$1.29B
Return on year-end equity	n/a	25.1%
Shares outstanding	5.44M	201.03M

n/a means the company did not report that line under the concept TickerFacts maps, not that it is zero.

Revenue, most recent five fiscal years

Fiscal year	20/20 Biolabs, Inc.	UL Solutions Inc.
Latest	$2.05M Ended 2025-12-31	$3.05B Ended 2025-12-31
1 year earlier	$1.75M Ended 2024-12-31	$2.87B Ended 2024-12-31
2 years earlier	n/a	$2.68B Ended 2023-12-31
3 years earlier	n/a	$2.52B Ended 2022-12-31
4 years earlier	n/a	n/a